The abstract is read at the publisher; the summary is JClub's.
A 3D concentric, three-compartment human bone marrow-on-a-chip builds an immunocompetent vascularized niche in ~7 d, enabling patient-derived testing of leukemia therapies.
- Why it matters: Bone marrow models often fail to reproduce patient-specific microenvironment biology and in vivo immune dynamics, limiting progress in leukemia immunotherapy development.
- What they did: The protocol assembles a microfluidic device, seeds stromal and hematopoietic cells, and uses patient-derived samples to evaluate CAR T cell therapy and chemotherapy with multiplexed readouts.
- The result: The chip supports live imaging, immunofluorescence, cytokine profiling, flow cytometry, and single-cell sequencing, with therapeutic testing typically run for 2 d to 14 d.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.